Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00310-0668-12 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug 17, 2017 In Use
63850-0060-01 63850-0060 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Mar 5, 2021 In Use
49884-0128-91 49884-0128 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Nov 29, 2022 In Use
73116-0225-56 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sep 28, 2018 In Use
72579-0017-01 72579-0017 Sonrotoclax BEQALZI 5.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
00245-0825-30 00245-0825 Everolimus TORPENZ 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 24, 2024 In Use
51991-0822-28 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Mar 5, 2021 In Use
00378-0007-85 00378-0007 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2021 In Use
46014-0296-01 46014-0296 talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0022-08 50881-0022 Ruxolitinib JAKAFI XR 22.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
63850-0058-01 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Mar 5, 2021 In Use
00378-3096-85 00378-3096 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec 15, 2022 Feb 28, 2025 No Longer Used
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous Apr 23, 2020 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec 20, 2019 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug 18, 2017 In Use
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sep 7, 2017 In Use
00074-1055-01 00074-1055 Telisotuzumab Vedotin EMRELIS 100.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sep 20, 2021 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
00074-1044-01 00074-1044 Telisotuzumab Vedotin EMRELIS 20.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
00173-0913-01 00173-0913 Belantamab mafodotin Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Oct 23, 2025 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Jun 10, 2019 In Use

Found 12611 results — Export these results